RxDoctor Payments Data

Evan Davidson, MD

Family Medicine · Louisville, KYNPI 1902245848

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 100 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$329
  • Gilead$309
  • E.r. Squibb & Sons, L.L.C.$257
  • Novo Nordisk$176
  • Johnson & Johnson$147
  • AbbVie$115
  • plus $758 from 23 others

What the payments were for

  • Food & beverage$1,99595%
  • Education$965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,090 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$188,869
Medicare patients
471
Services billed
2,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$99,900
OzempicSemaglutide66$61,971
XareltoRivaroxaban25$41,171
MounjaroTirzepatide24$24,979
JardianceEmpagliflozin12$20,025
JanuviaSitagliptin Phosphate12$19,385
TrulicityDulaglutide19$17,865
FarxigaDapagliflozin Propanediol13$13,768
SynthroidLevothyroxine Sodium48$3,971
Atorvastatin Calcium572$3,762
Levothyroxine Sodium312$3,313
Losartan Potassium291$2,465
Rosuvastatin Calcium252$2,329
Pantoprazole Sodium210$2,256
Amlodipine Besylate360$2,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$99,90090 claims
Novo NordiskOzempic$176$61,97166 claims
Lilly USA, LLCMounjaro, Trulicity$12$42,84443 claims
Johnson & JohnsonXarelto$147$41,17125 claims
Boehringer IngelheimJardiance$81$20,02512 claims
AstraZenecaFarxiga$33$13,76813 claims
AbbVieSynthroid$115$3,97148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →